A Comprehensive Review of Viscosupplementation in Osteoarthritis of the Knee

Orthopedic Reviews - Tập 13 Số 2
Jacquelin Peck1, Annabel Slovek2, Paulo Miro3, Neeraj Vij3, Blake Traube3, Christopher Lee4, Amnon A. Berger5, Hisham Kassem1, Alan D. Kaye6, William F. Sherman7, Alaa Abd‐Elsayed8
1Department of Anesthesiology, Mount Sinai Medical Center, Miami Beach, FL,
2Valley Anesthesiology and Pain Consultants -Envision Physician Services, Phoenix,
3Department of Anesthesiology, University of Arizona College of Medicine-Phoenix, AZ,
4Department of Internal Medicine, Creighton University School of Medicine-Phoenix Regional Campus, Phoenix, AZ,
5Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center–Harvard Medical School, Boston, MA
6Department of Anesthesiology, Louisiana State University Shreveport, LA,
7Department of Orthopaedic Surgery, Tulane University, New Orleans, LA,
8Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, WI

Tóm tắt

Purpose of Review

The purpose of this systematic review is to discuss emerging evidence in the field of viscosupplementation for chronic knee pain secondary to Osteoarthritis (OA). This review focuses on types of viscosupplementation that are clinically available currently, evidence to support their use, contraindications, and adverse events.

Recent Findings

OA, also known as degenerative joint disease, is the most common form of arthritis in the United States, affecting 54.4 million, or 22.7% of the adult population. The knee is the most common joint affected in OA, with up to 41% involvement, 30% in the hands, and 19% in the hips. The pathophysiology of OA is complex, with contributing factors including mechanical stress to the joint, as well as many person-specific factors such as genetic susceptibility, ethnicity, nutrition, and sex. Treatment modalities include weight control, exercise, non-steroidal and steroidal anti-inflammatory drugs, opioids, intra-articular platelet-rich plasma, placebo, corticosteroid injection, intra-articular viscosupplementation, and surgery. Viscosupplementation consists of injection of hyaluronic acid (HA) into affected joints, intending to restore the physiologic viscoelasticity in the synovial fluid (SF) in the absence of inflammation. HA has also been shown to downregulate pro-inflammatory factors, such as PGE2 and NFkB, and proteases and proteinases known to break down the joint matrix.

The contraindications for HA injection are similar to any other injection therapy, and adverse events are usually mild, local, and transient. Viscosupplementation (VS) is effective over placebo and more effective than NSAIDs and corticosteroids in pain reduction and improved functionality; however, guidelines recommend neither for nor against its use, demonstrating variability in the existing evidence base.

Current VS options divide primarily into native vs. cross-linked and low-molecular-weight vs. high-molecular-weight. Current treatment options include Hylan g-f-20, Sodium Hyaluronate preparations (Suparts Fx, Euflexxa, Gelsyn-3, Durolane, Hyalgen), single-use agents (Gel-One, Synvisc-One, Monovisc), and Hyaluronan (Orthovisc, Monovisc, Hymovic). They share a common safety profile, and all have evidence supporting their efficacy. Their specific details are reviewed here.

Summary

OA is the most common form of arthritis. It is a chronic, debilitating illness with a high impact on the functionality and quality of life of a significant part of the population in the western world. Treatments include medical management, physical therapy, activity modification, injection, and surgery. VS effectively reduces pain, increases functionality, and delays surgery in the knee to treat osteoarthritis. While previous studies have demonstrated variable results, more evidence is becoming available generally supportive of the benefit of VS in the treatment of knee OA.

Từ khóa


Tài liệu tham khảo

Florenzo Iannone, 2003, The pathophysiology of osteoarthritis., Aging clinical and experimental research, 15, 364, 10.1007/BF03327357

Juan C. Mora, 2018, Knee osteoarthritis: Pathophysiology and current treatment modalities, Journal of Pain Research, 11, 2189, 10.2147/JPR.S154002

Márcia Uchôa de Rezende, 2012, Viscosupplementation, Revista Brasileira de Ortopedia (English Edition), 47, 160, 10.1016/S2255-4971(15)30080-X

Hege Bothner, 1987, Rheology of hyaluronate, Acta Oto-Laryngologica, 104, 25, 10.3109/00016488709102834

C-T Wang, 2006, High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis., Osteoarthritis and cartilage, 14, 1237, 10.1016/j.joca.2006.05.009

, 2019, Patients. Hyalgan

Tadashi Yasuda, 2010, Hyaluronan inhibits prostaglandin E2 production via CD44 in U937 human macrophages., The Tohoku journal of experimental medicine, 220, 229, 10.1620/tjem.220.229

Akiko Sasaki, 2004, Hyaluronate inhibits the interleukin-1beta-induced expression of matrix metalloproteinase (MMP)-1 and MMP-3 in human synovial cells., The Tohoku journal of experimental medicine, 204, 99, 10.1620/tjem.204.99

, 2007, Three Treatments for Osteoarthritis of the Knee: Evidence Shows Lack of Benefit

N Bellamy, 2006, Viscosupplementation for the treatment of osteoarthritis of the knee., The Cochrane database of systematic reviews, CD005321, 10.1002/14651858.CD005321.pub2

Brian McGrory, 2016, The American Academy of Orthopaedic Surgeons Evidence-Based Clinical Practice Guideline on Surgical Management of Osteoarthritis of the Knee, The Journal of bone and joint surgery. American volume, 98, 688, 10.2106/JBJS.15.01311

Kamil E Barbour, 2017, Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015., MMWR. Morbidity and mortality weekly report, 66, 246, 10.15585/mmwr.mm6609e1

T E Mcalindon, 2014, OARSI guidelines for the non-surgical management of knee osteoarthritis, 10.1016/j.joca.2014.01.003

Marc C Hochberg, 2012, American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee, 10.1002/acr.21596

Anne W S Rutjes, 2012, Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis., Annals of internal medicine, 157, 180, 10.7326/0003-4819-157-3-201208070-00473

Pascal Richette, 2015, Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias., RMD Open, 1, e000071, 10.1136/rmdopen-2015-000071

Dan Xing, 2016, Intra-articular Hyaluronic Acid in Treating Knee Osteoarthritis: A PRISMA-Compliant Systematic Review of Overlapping Meta-analysis, Scientific Reports, 6, 10.1038/srep32790

2005, Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis., Ontario health technology assessment series, 5, 1

Larry W Moreland, 2003, Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action, Arthritis Research & Therapy, 5, 54, 10.1186/ar623

Manfred Wobig, 1999, The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: A comparison of hylan G-F 20 and a lower- molecular-weight hyaluronan, Clinical Therapeutics, 21, 1549, 10.1016/S0149-2918(00)80010-7

Hongmou Zhao, 2016, Hylan G-F 20 Versus Low Molecular Weight Hyaluronic Acids for Knee Osteoarthritis: A Meta-Analysis, BioDrugs, 30, 387, 10.1007/s40259-016-0186-1

Jennifer M Hootman, 2016, Updated Projected Prevalence of Self-Reported Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation Among US Adults, 2015-2040., Arthritis & rheumatology (Hoboken, N.J.), 68, 1582, 10.1002/art.39692

C. H. Yan, 2015, Efficacy and safety of hylan G-F 20 injection in treatment of knee osteoarthritis in Chinese patients: Results of a prospective, multicentre, longitudinal study, Hong Kong Medical Journal, 21, 327, 10.12809/hkmj144329

Seth S Leopold, 2002, Increased frequency of acute local reaction to intra-articular hylan GF-20 (synvisc) in patients receiving more than one course of treatment., The Journal of bone and joint surgery. American volume, 84, 1619, 10.2106/00004623-200209000-00015

Victor M Goldberg, 2004, Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment., Clinical orthopaedics and related research, 130, 10.1097/00003086-200402000-00021

M. Ishikawa, 2014, Biocompatibility of cross-linked hyaluronate (Gel-200) for the treatment of knee osteoarthritis, Osteoarthritis and Cartilage, 22, 1902, 10.1016/j.joca.2014.08.002

David D Waddell, 2016, Delayed Total Knee Replacement with Hylan G-F 20., The journal of knee surgery, 29, 159, 10.1055/s-0034-1395281

P. Kearey, 2017, Improvement in condition-specific and generic quality of life outcomes in patients with knee osteoarthritis following single-injection Synvisc: results from the LOBRAS study, Current Medical Research and Opinion, 33, 409, 10.1080/03007995.2016.1260533

Nattapol Tammachote, 2016, Intra-Articular, Single-Shot Hylan G-F 20 Hyaluronic Acid Injection Compared with Corticosteroid in Knee Osteoarthritis: A Double-Blind, Randomized Controlled Trial., The Journal of bone and joint surgery. American volume, 98, 885, 10.2106/JBJS.15.00544

Wen-Li Dai, 2019, Efficacy and Safety of Hylan versus Hyaluronic Acid in the Treatment of Knee Osteoarthritis., The journal of knee surgery, 32, 259, 10.1055/s-0038-1641142

Alberto Migliore, 2019, Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis, ClinicoEconomics and Outcomes Research, Volume 11, 453, 10.2147/ceor.s194669

Amy Bronstone, 2019, Supartz (Sodium Hyaluronate) for the Treatment of Knee Osteoarthritis: A Review of Efficacy and Safety, Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 12, 10.1177/1179544119835221

Ryan Bitton, 2009, The Economic Burden of Osteoarthritis, The American Journal of Managed Care, 15, 230, 10.1002/art.1780290311

Raveendhara R. Bannuru, 2016, Safety of Repeated Injections of Sodium Hyaluronate (SUPARTZ) for Knee Osteoarthritis: A Systematic Review and Meta-Analysis, Cartilage, 7, 322, 10.1177/1947603516642271

2018, EUFLEXXA for Osteoarthritis Knee Pain Three Injections Knee Joints.

Bioventus LLC, 2019, GELSYN-3, Bioventus OA Knee Pain Relief

K. Pavelka, 2011, Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial®) vs hylan G-F20 (Synvisc®) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study, Osteoarthritis and Cartilage, 19, 1294, 10.1016/j.joca.2011.07.016

Ross Leighton, 2018, Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis, Open Access Rheumatology: Research and Reviews, 10, 43, 10.2147/OARRR.S162127

Larry E. Miller, 2017, Long-term clinical benefit and cost-effectiveness of an 8-week multimodal knee osteoarthritis management program incorporating intra-articular sodium hyaluronate (Hyalgan®) injections, Journal of Pain Research, 10, 1045, 10.2147/JPR.S132497

Monique P Curran, 2010, Hyaluronic acid (Supartz®): a review of its use in osteoarthritis of the knee., Drugs Aging, 27, 925, 10.2165/11205920-000000000-00000

Patrice Vincent, 2019, Intra-Articular Hyaluronic Acid in the Symptomatic Treatment of Knee Osteoarthritis: A Meta-Analysis of Single-Injection Products, Current Therapeutic Research - Clinical and Experimental, 90, 39, 10.1016/j.curtheres.2019.02.003

David T. Felson, 1998, An update on the epidemiology of knee and hip osteoarthritis with a view to prevention, Arthritis and Rheumatism, 41, 1343, 10.1002/1529-0131(199808)41:8

Kathryn McElheny, 2019, Comparative Effectiveness of Alternative Dosing Regimens of Hyaluronic Acid Injections for Knee Osteoarthritis: A Systematic Review, Sports Health: A Multidisciplinary Approach, 11, 194173811986154, 10.1177/1941738119861545

Carrie Richardson, 2019, Intra-articular Hyaluronan Therapy for Symptomatic Knee Osteoarthritis, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2019.04.011

Rita C. Machado, 2017, Polysaccharides as viscosupplementation agents: Structural molecular characteristics but not rheology appear crucial to the therapeutic response, Frontiers in Medicine, 10.3389/fmed.2017.00082

Yanhong Han, 2019, Meta-analysis Comparing Platelet-Rich Plasma vs Hyaluronic Acid Injection in Patients with Knee Osteoarthritis, Pain Medicine, 20, 1418, 10.1093/pm/pnz011

Qingsong Li, 2018, Intra-articular oxygen-ozone versus hyaluronic acid in knee osteoarthritis: A meta-analysis of randomized controlled trials, International Journal of Surgery, 58, 3, 10.1016/j.ijsu.2018.08.007

Dario Gregori, 2018, Association of Pharmacological Treatments with Long-term Pain Control in Patients with Knee Osteoarthritis: A Systematic Review and Meta-analysis, JAMA - Journal of the American Medical Association, 320, 2564, 10.1001/jama.2018.19319

Andrew Concoff, 2017, The efficacy of multiple versus single hyaluronic acid injections: A systematic review and meta-analysis, BMC Musculoskeletal Disorders, 18, 10.1186/s12891-017-1897-2

Dongjun Shen, 2018, Efficacy of hyaluronic acid after knee arthroscopy: A systematic review and meta-analysis, Journal of Rehabilitation Medicine, 50, 860, 10.2340/16501977-2366

Yuqing Zhang, 2010, Epidemiology of osteoarthritis., Clinics in geriatric medicine, 26, 355, 10.1016/j.cger.2010.03.001

Stephanie C. Petterson, 2019, Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial, Knee Surgery, Sports Traumatology, Arthroscopy, 27, 1992, 10.1007/s00167-018-5114-0

Seihee Yoon, 2019, Efficacy and safety of intra-articular injections of hyaluronic acid combined with polydeoxyribonucleotide in the treatment of knee osteoarthritis, Annals of Rehabilitation Medicine, 43, 204, 10.5535/arm.2019.43.2.204

Shan Zheng Wang, 2018, Intra-articular, single-shot co-injection of hyaluronic acid and corticosteroids in knee osteoarthritis: A randomized controlled trial, Experimental and Therapeutic Medicine, 16, 1928, 10.3892/etm.2018.6371

Yong Huang, 2019, Intra-articular injections of platelet-rich plasma, hyaluronic acid or corticosteroids for knee osteoarthritis: A prospective randomized controlled study, Orthopade, 48, 239, 10.1007/s00132-018-03659-5

Ian J. Wallace, 2017, Knee osteoarthritis has doubled in prevalence since the mid-20th century, Proceedings of the National Academy of Sciences of the United States of America, 114, 9332, 10.1073/pnas.1703856114

Elena Losina, 2015, Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty., Arthritis care & research, 67, 203, 10.1002/acr.22412

Elena Losina, 2011, Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans., Annals of internal medicine, 154, 217, 10.7326/0003-4819-154-4-201102150-00001

Tuhina Neogi, 2013, Epidemiology of OA, Rheum Dis Clin North Am, 39, 1, 10.1016/j.rdc.2012.10.004

Job Hermans, 2019, The effectiveness of high molecular weight hyaluronic acid for knee osteoarthritis in patients in the working age: A randomised controlled trial, BMC Musculoskeletal Disorders, 20, 10.1186/s12891-019-2546-8

Yves Henrotin, 2019, Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: Data from MOKHA study, BMC Musculoskeletal Disorders, 20, 10.1186/s12891-019-2667-0

Demirhan Diraçoǧlu, 2016, Single versus multiple dose hyaluronic acid: Comparison of the results, Journal of Back and Musculoskeletal Rehabilitation, 29, 881, 10.3233/BMR-160714

, Frequestly Asked Questions, Synvisc-One® Official Site

Chul Won Ha, 2017, Efficacy and safety of single injection of cross-linked sodium hyaluronate vs. three injections of high molecular weight sodium hyaluronate for osteoarthritis of the knee: A double-blind, randomized, multi-center, non-inferiority study, BMC Musculoskeletal Disorders, 18, 1, 10.1186/s12891-017-1591-4